Skip to main content
Premium Trial:

Request an Annual Quote

Lab21 Raises $3.2M in Private Round of Financing

NEW YORK (GenomeWeb News) – Diagnostics products and services firm Lab21 today said that it has raised £2.2 million ($3.2 million) from a round of financing with private equity investors.
 
The Cambridge, UK-based firm, which has diagnostics products and services focused on infectious diseases, oncology, and pharmacogenetics, said it would use the funds to further its acquisition plan and to establish its US operations in South Carolina with an eye toward expanding its North American presence.
 
Boston-based Nexus Medical Partners and UK-based Rowan Dartington participated in the round and join Merlin Biosciences and Kreos Capital as shareholders. As part of the investment, Ed Snape, co-founder and head of the healthcare practice for Nexus, will join the board of Lab21.
 
Lab21 expects to complete two acquisitions in Europe in the first half of 2009.
 
Among the firm’s diagnostic services offerings are molecular tests for cytochrome P450 and DxS’ KRAS assay.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.